EUCTR2016-001615-21-IT进行中（未招募）1 期
A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616 in Boys with Duchenne Muscular Dystrophy
Pfizer Inc. 235 East 42nd Street, New York, NY 100170 个研究点目标入组 59 人开始时间: 2017年1月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Subjects with Duchenne muscular dystrophy who enrolled and completed through Week 97 of Study B5161002.
- •2. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject’s parent or legal guardian/caregiver has been informed of all pertinent aspects of the study. Subjects may be required to provide assent in compliance with local regulations and IRB requirements.
- •3. Subjects and their legal guardians/caregivers who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •4. The following inclusion criteria will be assessed using data from the B5161002 study, and if data are unavailable, these assessments must be completed prior to enrollment:
- •a. Adequate hepatic function on screening laboratory assessments from the Week 97 visit.
- •b. GLDH = 20 units/liter (2 x upper limit of normal [ULN]) from the Week 97 visit.
- •c. Iron content estimate on the liver MRI within the normal range as determined by R2* value (R2*=75 Hz at 1.5 T or R2*=139 Hz at 3.0 T) from the Week 93 visit.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 105
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Unwilling or unable (eg, metal implants) to undergo examination with closed MRI. If subjects required sedation in the B5161002 study they will be permitted to enroll in the OLE. In the event that a subject becomes intolerant to MRI scanning, during the OLE, the subject may be separately consented to be administered sedation in order to complete the MRI.
- •2. All male subjects who are able to father children and are sexually active and at risk for impregnating a female partner, who are unwilling or unable to use with their female partner(s) a highly effective method of contraception consistently and correctly for the duration of the active treatment period and through the final study visit. In addition, all sexually active male subjects who are unwilling or unable to prevent potential transfer of and exposure to drug through semen to their partners by using a condom consistently and
- •correctly, beginning with the first dose of investigational product and continuing through the final study visit.
- •3. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are related to Pfizer employees directly involved in the conduct of the study.
- •4. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •5. Participation in other studies involving investigational drug(s), with the exception of B5161002, for a minimum of 30 days or within 5 half-lives (whichever is longer) prior to signing the informed consent and/or during study participation.
- •6. History of allergic or anaphylactic reaction to a therapeutic or diagnostic protein or additives of this investigational product (histidine, sucrose, edetic acid [ethylenediaminetetraacetic acid], and polysorbate 80).
研究者
相似试验
进行中（未招募）
1 期
An extension to Protocol B5161002 to evaluate the long-term safety of as well as to collect data regarding maintenance of effect up to 4 yearsEUCTR2016-001615-21-BGPfizer Inc. 235 East 42nd Street, New York, NY 1001759
进行中（未招募）
1 期
A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing SpondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersAnkylosing SpondylitisEUCTR2017-001002-15-ESCB Biopharma SPR285
进行中（未招募）
1 期
A Study to Evaluate the Long Term Safety and Efficacy ofBimekizumab in Subjects with Ankylosing SpondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersAnkylosing SpondylitisEUCTR2017-001002-15-DECB BIOPHARMA SR285
进行中（未招募）
1 期
A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing SpondylitisAnkylosing SpondylitisEUCTR2017-001002-15-BGCB Biopharma SR285
进行中（未招募）
1 期
A Study to Evaluate the Long Term Safety and Efficacy ofBimekizumab in Subjects with Ankylosing SpondylitisAnkylosing SpondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-001002-15-HUCB BIOSCIENCES GmbH285